AWM
VRTX icon

AE Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

AE Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
3,924
+1,194
+44% +$557K 0.01% 685
2025
Q4 		$1.24M Buy
2,730
+958
+54% +$413K 0.01% 741
2025
Q3 		$694K Sell
1,772
-696
-28% -$291K ﹤0.01% 855
2025
Q2 		$1.1M Buy
2,468
+1,304
+112% +$601K 0.01% 699
2025
Q1 		$564K Sell
1,164
-1
-0.1% -$466 ﹤0.01% 881
2024
Q4 		$469K Buy
1,165
+29
+3% +$13.4K ﹤0.01% 934
2024
Q3 		$528K Sell
1,136
-31
-3% -$14.9K ﹤0.01% 873
2024
Q2 		$547K Sell
1,167
-166
-12% -$72.1K 0.01% 859
2024
Q1 		$557K Sell
1,333
-21,275
-94% -$8.99M 0.01% 788
2023
Q4 		$9.73M Buy
22,608
+1,710
+8% +$632K 0.05% 402
2023
Q3 		$7.27M Buy
20,898
+4,351
+26% +$1.52M 0.04% 449
2023
Q2 		$5.82M Buy
16,547
+14,732
+812% +$4.96M 0.04% 494
2023
Q1 		$572K Sell
1,815
-3,181
-64% -$954K ﹤0.01% 1284
2022
Q4 		$1.44M Buy
4,996
+3,552
+246% +$1.08M 0.01% 857
2022
Q3 		$418K Buy
1,444
+227
+19% +$65.3K ﹤0.01% 1348
2022
Q2 		$343K Buy
1,217
+271
+29% +$72.5K ﹤0.01% 1380
2022
Q1 		$247K Buy
+946
New +$225K ﹤0.01% 1504
2021
Q3 		– Sell
-1,027
Closed -$207K – 1721
2021
Q2 		$207K Sell
1,027
-11,804
-92% -$2.47M ﹤0.01% 1494
2021
Q1 		$2.76M Buy
12,831
+11,782
+1,123% +$2.59M 0.03% 482
2020
Q4 		$248K Sell
1,049
-3,355
-76% -$770K ﹤0.01% 1205
2020
Q3 		$1.2M Buy
4,404
+2,111
+92% +$582K 0.02% 584
2020
Q2 		$666K Sell
2,293
-1,795
-44% -$487K 0.01% 755
2020
Q1 		$973K Buy
4,088
+2,324
+132% +$533K 0.02% 496
2019
Q4 		$386K Buy
+1,764
New +$357K 0.01% 818

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AE Wealth Management's VRTX Position: Q1 2026 in Review

AE Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q1 2026, buying an estimated $557K and bringing the position to 3,924 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #685.

AE Wealth Management first reported a position in VRTX in Q4 2019 and has held it in 24 quarters since. The position peaked at $9.73M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • AE Wealth Management held 3,924 shares of Vertex Pharmaceuticals worth $1.75M as of Q1 2026.
  • AE Wealth Management bought 1,194 Vertex Pharmaceuticals shares in Q1 2026, an estimated $557K.
  • Vertex Pharmaceuticals made up 0.01% of AE Wealth Management's portfolio in Q1 2026, its #685 holding.
  • AE Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • AE Wealth Management's Vertex Pharmaceuticals position peaked at $9.73M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on AE Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.